Imaging of Osteoarthritis

Osteoarthritis (OA) is the most prevalent joint disorder in the elderly, and there is no effective treatment. Imaging is essential for evaluating the synovial joint structures (including cartilage, meniscus, subchondral bone marrow and synovium) for diagnosis, prognosis, and follow-up. This article describes the roles and limitations of both conventional radiography and magnetic resonance (MR) imaging, and considers the use of other modalities (eg, ultrasonography, nuclear medicine, computed tomography [CT], and CT/MR arthrography) in clinical practice and OA research. The emphasis throughout is on OA of the knee. This article emphasizes research developments and literature evidence published since 2008

Magnetic Resonance Imaging of synovitis without the use of intravenous gadolinium.

Synovitis is an important feature in arthritis and is commonly visualised using contrast enhanced magnetic resonance imaging (MRI). Currently, the reference standard for assessing synovitis is gadolinium enhanced MRI which requires an intravenous injection and carries significant potential risks such as nephrogenic systemic fibrosis. Removing the necessity for using gadolinium will reduce these risks and result in greater patient acceptance of MRI investigation of synovitis. The aims of this thesis were to investigate the use of MRI imaging sequences and include them in a novel non-contrast MRI protocol, The COSMOS protocol (contrast-obviated MRI scanning of synovitis) to identify synovitis in the knees of patients with osteoarthritis. Potential sequences, both qualitative and quantitative, that could be included in the COSMOS protocol were identified initially through (i) a comprehensive review of the literature and (ii) review of historic images within a large research centre. The sequences were then trialled, optimised and then assessed on a large cohort of patients with knee osteoarthritis in order to determine the protocol’s suitability to identify synovitis without contrast. The results of the new COSMOS protocol show that it is feasible and practical to delineate synovitis in the knee using MRI without the use of intravenous gadolinium contrast. The characteristics of the tissues within the knee can be measured using magnetisation transfer ratio and T1 values to provide empirical differentiation of structures. The identification of a distinct range in T1 values for synovitis provided data that was exploited to produce a further inversion recovery sequence that was optimised to supress synovitis in patients with knee osteoarthritis (OA). While further work is required to validate the COSMOS protocol, this thesis has demonstrated that it is possible to image synovitis without intravenous gadolinium contrast agents in a cohort of patients with a clinical diagnosis of OA knee

Artificial intelligence in musculoskeletal ultrasound imaging

Ultrasonography (US) is noninvasive and offers real-time, low-cost, and portable imaging that facilitates the rapid and dynamic assessment of musculoskeletal components. Significant technological improvements have contributed to the increasing adoption of US for musculoskeletal assessments, as artificial intelligence (AI)-based computer-aided detection and computer-aided diagnosis are being utilized to improve the quality, efficiency, and cost of US imaging. This review provides an overview of classical machine learning techniques and modern deep learning approaches for musculoskeletal US, with a focus on the key categories of detection and diagnosis of musculoskeletal disorders, predictive analysis with classification and regression, and automated image segmentation. Moreover, we outline challenges and a range of opportunities for AI in musculoskeletal US practice.11Nsciescopu

The impact of MRI on the clinical management of inflammatory arthritides

In the past two decades, MRI has gained a major role in research and clinical management of patients with inflammatory arthritides, particularly in spondyloarthritis (SpA), rheumatoid arthritis (RA), and osteoarthritis (OA). MRI is regarded as the most sensitive imaging modality for detecting early SpA in young patients with inflammatory back pain and normal radiographs of the sacroiliac joints. The recently published Assessment of SpondyloArthritis International Society classification criteria for axial SpA include for the first time a positive MRI demonstrating sacroiliitis as an imaging criterion indicative of SpA together with at least one clinical feature of SpA. Recent data show that systematic assessment of sacroiliitis displayed on MRI has much greater diagnostic utility than previously reported and highlight the diagnostic relevance of structural lesions. In RA, MRI has predictive value for the development of disease in new onset undifferentiated arthritis, and MR pathology at disease onset is a highly significant predictor of radiographic erosions. Consequently MRI has been credited with an important role in the new ACR/EULAR 2010 classification criteria for RA. In OA, bone marrow edema (BME) and synovitis may serve as biomarkers in interventional trials. Treatment interventions targeting BME and synovitis observed on MRI in inflammatory arthritides may have a disease-modifying effect as these lesions are potentially reversible and have been shown to be associated with structural progression. Research should focus on the prognostic significance of MRI lesions in larger cohorts and whether adding MRI to routine care improves clinical and radiographic outcome in patients with inflammatory arthritide

A Phase II Trial of Lutikizumab, an Anti–Interleukin‐1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis

Objective: To assess the efficacy and safety of the anti–interleukin‐1α/β (anti–IL‐1α/β) dual variable domain immunoglobulin lutikizumab (ABT‐981) in patients with knee osteoarthritis (OA) and evidence of synovitis. Methods: Patients (n = 350; 347 analyzed) with Kellgren/Lawrence grade 2–3 knee OA and synovitis (determined by magnetic resonance imaging [MRI] or ultrasound) were randomized to receive placebo or lutikizumab 25, 100, or 200 mg subcutaneously every 2 weeks for 50 weeks. The coprimary end points were change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score at week 16 and change from baseline in MRI‐assessed synovitis at week 26. Results: The WOMAC pain score at week 16 had improved significantly versus placebo with lutikizumab 100 mg (P = 0.050) but not with the 25 mg or 200 mg doses. Beyond week 16, the WOMAC pain score was reduced in all groups but was not significantly different between lutikizumab‐treated and placebo‐treated patients. Changes from baseline in MRI‐assessed synovitis at week 26 and other key symptom‐ and most structure‐related end points at weeks 26 and 52 were not significantly different between the lutikizumab and placebo groups. Injection site reactions, neutropenia, and discontinuations due to neutropenia were more frequent with lutikizumab versus placebo. Reductions in neutrophil and high‐sensitivity C‐reactive protein levels plateaued with lutikizumab 100 mg, with further reductions not observed with the 200 mg dose. Immunogenic response to lutikizumab did not meaningfully affect systemic lutikizumab concentrations. Conclusion: The limited improvement in the WOMAC pain score and the lack of synovitis improvement with lutikizumab, together with published results from trials of other IL‐1 inhibitors, suggest that IL‐1 inhibition is not an effective analgesic/antiinflammatory therapy in most patients with knee OA and associated synovitis

Imaging of Osteoarthritis and Rheumatoid Arthritis in Hand Joints

The aims of this thesis can be summarized as: - to assess construct validity and reliability of direct cartilage imaging with MRI in hand OA. - to asses if CT has better reliability and detection rate of thumb base OA than conventional radiography. - to assess construct validity of low-field extremity MRI in early arthritis patients